SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
AGMB

AgomAb Therapeutics NV (NASDAQ:AGMB)

BE · Delayed Price · Currency is USD
Healthcare · Biotechnology
$5.45-$0.17 (-3.02%)
 
Market cap
$268M
Insider Score
Health Score
Listed since
Feb 6, 2026
Website
Market Cap$268.40M-62.8%
Revenue (ttm)$0
Net Income-$35.68M
EPS-$0.79
Shares Out49.25M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume188,938
Open$5.51
Previous Close$5.62
Day's Range$5.42 - $5.78
52-Week Range$5.39 - $17.82
Beta1.80
Analystsn/a
Price Target$35.00(+542.20%)
Earnings DateMar 3, 2027

About AGMB

AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials. Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF. This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.

Address
Posthoflei 1/6, Antwerp, VL, 2600, BE
Market Cap
268 million
Employees
62
Industrial Classification
Biotechnology

AgomAb Therapeutics NV Stock Analysis — InsiderScore

Insider Score
See top-rated InsiderScore stocks ›
51st Percentile Overall Score
AGMB InsiderScore:68 / 99

AgomAb Therapeutics NV scored higher than 51% of companies evaluated by InsiderBuying, and ranked 37th out of 110 stocks in the biotech sector.

Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.

Dollars Committed

Insiders at AgomAb Therapeutics NV bought $620.0K of stock across 18 purchases in the last 90 days, the largest of them $50.9K.

Stake Increase

The average purchase added about 24% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.

New Positions

2 of these purchases were made by someone who held no stock at all beforehand — going from nothing to a position is the strongest form of this signal.

This category carries 35% of the Insider Score.

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$620.00K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

When insiders bought and sold

1 year · open-market trades only
Closing Price Purchase Sale
$5.01$11.86$18.71MarMayJulSepNov
Financial Health Score
Fair
From AGMB’s reported statements · FY2025 · 4 of 5 pillars

Next catalysts

1 Day
-3.02%
5 Days
-14.31%
1 Month
-41.14%
6 Months
-52.61%
1 Year
-62.80%

$AGMB stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in AGMB holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by AGMB's directors and management

Net Shares Purchased by Insiders−90k−45k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

AGMB Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New AGMB patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to AGMB from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in AGMB

SBIOALPS Medical Breakthroughs ETF$326.06K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from AGMB’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
66.97
Analyst Ratings
40% of score
99
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
18
Sells
0
Buy Value
$620.00K
Distinct Buyers
3

Insider Score Trend Over Time

-30.0 since Oct 7
0255075100Oct 7 — Insider Score 98.1Oct 8 — Insider Score 68.1Oct 9 — Insider Score 68.3Oct 10 — Insider Score 68.2Oct 11 — Insider Score 68.3Oct 12 — Insider Score 68.3Oct 13 — Insider Score 68.3Oct 14 — Insider Score 68.1Oct 15 — Insider Score 68.1Oct 16 — Insider Score 68.0Oct 17 — Insider Score 68.0Oct 18 — Insider Score 68.0Oct 19 — Insider Score 68.0Oct 20 — Insider Score 68.0Oct 21 — Insider Score 68.0Oct 22 — Insider Score 68.0Oct 23 — Insider Score 68.0Oct 24 — Insider Score 68.0Oct 25 — Insider Score 68.2Oct 26 — Insider Score 68.2Oct 27 — Insider Score 68.2Oct 28 — Insider Score 68.2Oct 29 — Insider Score 68.2Oct 30 — Insider Score 68.1Oct 31 — Insider Score 68.1Nov 1 — Insider Score 68.1Nov 2 — Insider Score 68.2Nov 3 — Insider Score 68.1Nov 4 — Insider Score 68.0Nov 5 — Insider Score 67.9Nov 6 — Insider Score 67.8Nov 7 — Insider Score 68.2Nov 8 — Insider Score 68.3Nov 9 — Insider Score 68.3Nov 10 — Insider Score 68.1Nov 11 — Insider Score 68.1Nov 12 — Insider Score 68.0Nov 13 — Insider Score 67.8Nov 14 — Insider Score 67.8Nov 15 — Insider Score 67.8Nov 16 — Insider Score 68.3Nov 17 — Insider Score 68.1Nov 18 — Insider Score 68.0Nov 19 — Insider Score 68.2Nov 20 — Insider Score 68.1Nov 21 — Insider Score 68.0Nov 22 — Insider Score 68.1Oct 7Oct 30Nov 22

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

SBIOALPS Medical Breakthroughs ETF0.20%

Weight is the stock’s share of each fund’s holdings.